Potential Role of Vitamin B6 in Ameliorating the Severity of COVID-19 and Its Complications

Thanutchaporn Kumrungsee 1*, Peipei Zhang 2, Maesaya Chartkul 3,4,5, Noriyuki Yanaka 1 and Norihisa Kato 1*

1 Graduate School of Integrated Sciences for Life, Hiroshima University, Higashi-Hiroshima, Japan, 2 State Key Laboratory of Cellular Stress Biology, School of Medicine and School of Life Science, Xiamen University, Xiamen, China, 3 Emergency Department, Bangkok Chanthaburi Hospital, Chanthaburi, Thailand, 4 Emergency Department, King Prajadhipok Memorial Hospital, Chanthaburi, Thailand, 5 Department of Preventive and Social Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

Keywords: vitamin B6, COVID-19, pneumonia, cardiovascular diseases, diabetes, inflammasome, oxidative stress, carnosine

INTRODUCTION

The word is currently experiencing a coronavirus disease-19 (COVID-19) pandemic caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Coronaviruses and influenza are among the viruses that can cause lethal lung injuries and death from acute respiratory distress syndrome worldwide (1). Viral infections evoke a “cytokine storm,” leading to lung capillary endothelial cell inflammation, neutrophil infiltration, and increased oxidative stress (1, 2). Furthermore, cardiovascular and diabetic complications are emerging in COVID-19 patients (3–9). Currently, there is no registered treatment or vaccine for COVID-19, and an alternative solution to protect against COVID-19 is urgently needed.

Vitamin B6 is a water-soluble vitamin found in various foods such as fish, whole grains, and banana (10). There are six isoforms of B6 vitamers (10). Among these, pyridoxal 5’-phosphate (PLP) is the most active form that acts as a coenzyme in various enzymatic reactions (10). There is growing evidence that vitamin B6 exerts a protective effect against chronic diseases such as cardiovascular diseases (CVD) and diabetes by suppressing inflammation, inflammasomes, oxidative stress, and carbonyl stress (11). Additionally, vitamin B6 deficiency is associated with lower immune function and higher susceptibility to viral infection (12, 13). In view of these information, we postulated potential role of vitamin B6 in ameliorating the severity of COVID-19 and its complications (Figure 1). In this article, we review precedent research to test this hypothesis.

PATHOGENESIS OF COVID-19 INFECTION

COVID-19 and Its Complications

Recent studies suggest that COVID-19 patients are likely to have chronic diseases (32–86%), among which hypertension (15–49%), CVD (6–40%), and diabetes (10–30%) (4–9) are most commonly reported worldwide. For example, in China, of 138 patients, 46% had a pre-existing chronic disease, including hypertension (31%), CVD (15%), and diabetes (10%) (5). In Italy, of 1,043 cases, 80% had chronic disease, with the top three being diabetes (10%), chronic lung disease (9.2%), and CVD (9.0%) (7). In Thailand, the first country outside of China to report a COVID-19 case (14), among the 54 patients who died (up to May 2, 2020), 65% had underlying diseases, and the top three diseases were diabetes
(30%), hypertension (17%), kidney disease (13%), and CVD (6%) (Supplementary Table) (9). Besides these comorbidities, high cumulative incidence of thrombotic complications was found in critically ill patients with COVID-19 pneumonia in Dutch hospitals (15). In addition to the above data, evidence suggests that male and older populations are more susceptible to viral infection (4–8). Thus, these groups and patients with chronic diseases are more likely to require critical care.

**COVID-19 and Endothelial Cell Inflammation**

COVID-19 is caused by SARS-CoV2. The virus mainly enters the body by binding to the angiotensin converting enzyme (ACE) 2 receptor, which is highly expressed in lung alveolar cells and epithelial cells in the respiratory tract, thus causing lung injury (1). Besides cells in the airways, the ACE2 receptor is highly expressed in cardiac and vascular endothelial cells (1, 2), which potentially make heart and blood vessels target organs for the virus. This may explain common cardiovascular complications with poor outcomes in COVID-19 patients with CVD and hypertension. Post-mortem analysis of COVID-19 patients revealed direct viral infection and inflammation of endothelial cells causing endothelial dysfunction and apoptosis subsequent to vascular leakage in many organs (2). Since blood vessels traverse multiple organs, this may partly explain systemic inflammation and multi-organ failure, commonly found in COVID-19 patients.

Another feature of COVID-19 is cytokine storm, resulting from excessive and aberrant host immune responses (1, 3). Studies of COVID-19 patients’ serum show lymphopenia and a marked increase in inflammatory markers such as interleukin-6 (IL-6) and C-reactive protein (CRP). These are commonly observed parameters linked to disease severity (4–6). Thus, it can be hypothesized that for chronic inflammatory diseases such as diabetes where the immune response is impaired, abnormal immune activation and hyperinflammation in COVID-19 possibly make patients more susceptible to viral infection.

Taken together, agents that can moderate immune function and inflammation, maintain endothelial cell integrity, and ameliorate chronic diseases may be useful in reducing the severity of and/or curing COVID-19. In this paper, we will analyze this problem in terms of nutrition. The rationale for using vitamin B6 as a possible adjuvant treatment for COVID-19 is discussed in the following sections.

**VITAMIN B6 AND CARDIOVASCULAR DISEASES**

Evidence suggests that a low dietary intake of vitamin B6 is associated with a high risk of mortality risk from CVD, and vitamin B6 supplementation reduces this risk (11, 16). In humans, low PLP plasma levels are associated with a high risk of CVD, atherosclerosis, stroke, and thrombosis (11, 16). Recently, the role of vitamin B6 in CVD risk has been addressed through chronic inflammation, a crucial mechanism underlying atherosclerosis and CVD progression. Plasma PLP levels were inversely correlated with systemic inflammation markers such as CRP (17). Vitamin B6 supplementation suppressed IL-6 and increased total lymphocytes in patients with chronic conditions (18). Notably, both an increase in CRP and IL-6 and a decrease in lymphocytes were common in COVID-19 patient sera (4–6). Recently, novel heart protective effects of vitamin B6 have been proposed such as regulating homeostasis of imidazole dipeptides, e.g., carnosine and anserine which are cardioprotectors with antioxidant and anti-inflammatory activities (11, 19). Vitamin B6 can also regulate cellular calcium influx through both voltage-mediated and ATP-mediated purinergic mechanisms, which suggests its role in regulating hypertension and cardio-dysfunction (20). In line with this, vitamin B6 supplementation showed blood pressure lowering effect in hypertensive patients (21). Additionally, oral administration of vitamin B6 attenuates platelet aggregation and clot formation (22). Taken together, it can be suggested that vitamin B6 may ameliorate the severity of COVID-19 by preventing worsening of CVD complications through those beneficial actions.

**VITAMIN B6 AND DIABETES**

Vitamin B6 has been found to be associated with diabetes, wherein blood PLP levels are lower in these patients (23). Studies have demonstrated that vitamin B6 supplementation reduces the incidence of diabetes and its complications (24, 25). Vitamin B6 deficiency is associated with insulin-glucagon dysregulation, glucose tolerance, and β-cell degeneration (24). Since vascular disease is a hallmark of diabetic complications,
this may explain the comorbidities of CVD, hypertension, and diabetes in COVID-19. Vitamin B6 was even found to play a beneficial role in vascular endothelial function in diabetic patients (26). Among the B6-vitamers, pyridoxamine has anti-glycation activity and inhibits the formation of advanced glycation end-products (AGEs) that are major mediators of inflammation, oxidative stress, and endothelial-vascular wall damage (27). Increase in AGEs is implicated in initiation and progression of diabetes-associated microvascular diseases, major diabetic complications. Based on these notions, we can assume that sufficient vitamin B6 levels are beneficial to suppress severity of COVID-19, partly through ameliorating diabetic complications.

VITAMIN B6 AND PNEUMONIA

In 1949, Leftwich and Mirick reported a preventive effect of vitamin B6 against viral infection (13). Mice fed a vitamin B6-deficient diet were more susceptible to infection of murine pneumonia virus than control mice. Shan et al. recently indicated that vitamin B6 administration remarkably inhibited LPS-induced systemic inflammation and acute pneumonia in mice (28). Key events linked to infection with respiratory viruses are associated with oxidative stress, inflammation, and subsequent lung injury. In fact, oral administration of anti-oxidants such as carnosine and N-acetylcysteine exerted beneficial effects on lung injury (29, 30). These suggest that vitamin B6 may ameliorate the severity of COVID-19 by exerting its anti-oxidative and anti-inflammatory actions in lung, a primary target organ for COVID-19 virus infection.

VITAMIN B6 AND IMMUNE FUNCTION

Vitamin B6 supplementation improved immune function in both human and animal studies (10), and vitamin B6 deficiency led to impairment of various facets of immunity such as lymphoid atrophy and reduced lymphocyte numbers (12). It improves the immune response, causing increased antibody production, and enhances communicative interactions between cytokines and chemokines (31). Thus, its deficiency may lead to suppressed immunity predisposing patients to infections. A previous study has implicated the lipid mediator sphingosine 1-phosphate (SIP) in vitamin B6-mediated immune regulation (32, 33). SIP regulates cell trafficking, especially cell egress from organized lymphoid tissues in thymus, bone marrow, lymph nodes, and intestinal mucosa (33). Cell trafficking is determined by the SIP gradient through SIP production and degradation mediated by SIP lyase and SIP phosphohydrolase (33). Since SIP lyase requires PLP as a coenzyme for SIP degradation, its deficiency impairs SIP lyase activity and elevates SIP levels. This in turn impairs lymphocyte trafficking from lymphoid tissues and reduces lymphocyte numbers in the peripheral tissues (32, 33).

VITAMIN B6 AND INFLAMMASOME

Canonical inflammasomes are cytoplasmic multiprotein complexes that activate caspase-1 in response to a variety of physiological and pathogenic stimuli (11, 34), leading to a downstream cascade of inflammatory response through the release of inflammatory modulators, such as Interleukin-1β (IL-1β) and interleukin-18 (IL-18) (11, 34). Among the various inflammasomes, NLRP3 inflammasome in macrophages, endothelial cells, and epithelial cells responds to a broad variety of stimuli, particularly viral RNA and its components (35, 36). NLRP3 inflammasome activation plays an important role in virus clearing by innate immunity; however, overactivation promotes inflammatory cell and host cell death (11, 34). Recently, vitamin B6 was shown to reduce IL-1β production by suppressing NLRP3 inflammasome responded to various NLRP3 inflammasome stimuli (37). Furthermore, vitamin B6 markedly reduced reactive oxygen species (ROS) production in peritoneal macrophages, where it plays a central role in NLRP3 inflammasome activation (37). It is suggested that at an early stage in the infection to macrophages, endothelial cells, and epithelial cells, SARS-CoV2 potentially escapes innate immune, thereby increasing the viral replication (1). Then, those infected cells undergo cell death, causing acute virus spread and severe cytokine storm. Here, we assume that vitamin B6 is possible to suppress hyperinflammation, at least in part, through NLRP3 inflammasome inhibition, limiting virus spread and cytokine storm. Together with the notion that NLRP3 inflammasome plays a central role in chronic diseases, including CVD, diabetes, and acute viral pneumonia (38–40), the anti-inflammasome effect of vitamin B6 suggest its therapeutic role in reducing the severity of COVID-19 and its complications.

VITAMIN B6 AND OXIDATIVE STRESS

Since the discovery of B6-vitamers as ROS scavengers (41, 42), evidence indicates an inverse association between vitamin B6-deficient status and higher oxidative stress (11, 43). Studies indicate that B6-vitamers can reduce superoxide radical and lipid peroxide levels induced by H2O2 in vascular endothelial cells (44). Emerging evidence suggests that hydrogen sulfide (H2S) exerts strong anti-oxidant and anti-inflammatory effects at low levels (45). In the liver and cardiovascular tissues, H2S formation involves a PLP-dependent enzyme, cystathionine β-lyase, which is affected by vitamin B6 levels (45). Our recent studies revealed that vitamin B6 supplementation to a marginal-vitamin B6 deficient diet caused a remarkable increase in levels of imidazole dipeptides, carnosine and anserine, in heart and skeletal muscle of rats, possibly by modulating PLP-enzymes for biosynthesis (11, 19). Carnosine has various health benefits, including anti-oxidant, anti-inflammatory, anti-glycation, anti-ischemic, anti-cognitive, anti-aging, and ergogenic effects (11, 46). Thus, vitamin B6 may help to maintain a healthy defense system for the body to fight oxidative stress associated with virus infection.
CONCLUSION

Here, we summarized the available evidence suggesting the potential role of vitamin B6 in suppressing the severity of COVID-19 possibly through ameliorating complications of chronic diseases such as hypertension, CVD, and diabetes. Clinical studies in COVID-19 patients are urgently needed to confirm these possibilities. In spite of the lungs being a primary target organ for SARS-CoV2 infection, information regarding the role of nutrition in lung health is very limited. Considering the emergence of new viruses, nutrition studies on the lungs, a primary target of airborne viral infections, should be performed. Severe vitamin B6 deficiency is relatively uncommon, but some individuals might have marginal vitamin B6 deficiency. Vitamin B6 can be easily available as a dietary supplement with low cost and health risk. Accumulating evidence suggests that vitamin B6 supplementation may be useful for COVID-19 patients with low vitamin B6 status.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2020.562051/full#supplementary-material

REFERENCES

1. Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: and treatment options. Clin Immunol. (2020) 215:108448. doi: 10.1016/j.clim.2020.108448
2. Varga Z, Flammer AJ, Steiger P, Haberrecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endothelitis in COVID-19. Lancet. (2020) 395:1417–8. doi: 10.1016/S0140-6736(20)30937-5
3. Wang L, Zhang Y, Zhang S. Cardiovascular impairment in COVID-19: learning from current options for cardiovascular anti-inflammatory therapy. Front Cardiovasc Med. (2020) 7:78. doi: 10.3389/fcm.2020.00078
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5
5. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. (2020) 323:1061–9. doi: 10.1001/jama.2020.1585
6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13. doi: 10.1016/S0140-6736(20)30211-7
7. Grasselli G, Zaninotto A, Zanello A, Antonelli M, Caburni L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. (2020) 323:1574–81. doi: 10.1001/jama.2020.5394
8. Chow N, Flemming-Dutra K, Gierke R, Hall A, Hughes M, Pilishvili T, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020. Morb Mortal Wkly Rep. (2020) 69:382–6.
9. Thai PBS. LIVE. (2020). Available online at: https://covid19.thaipbs.or.th/live/ (accessed May 2, 2020).
10. Ueland PM, McCann A, Midttun Ø, Olvik A. Inflammation, vitamin B6 and related pathways. Mol Aspects Med. (2017) 53:10–27. doi: 10.1016/j.mam.2016.08.001
11. Zhang P, Suda T, Suidasari S, Kumrungsee T, Yanaka N, Kato N. Novel preventive mechanisms of vitamin B6 against inflammation, inflammation and chronic diseases. In: Vinood BP, editor. Molecular Nutrition. Cambridge, MA: Academic Press (2020). p. 283–99. doi: 10.1016/B978-0-12-811907-5.00032-4
12. Rail LC, Meydani SN. Vitamin B6 and immune competence. Nutr Rev. (1993) 51:217–25. doi: 10.1111/j.1753-4887.1993.tb03109.x
13. Mirick GS, Leftwich WB. The effect of diet on the susceptibility of the mouse to Pneumonia Virus of mice (PVM) II. Influence of pyridoxine administered in the period before as well as after the inoculation of virus. J Exp Med. (1949) 89:175–84. doi: 10.1084/jem.89.2.175
14. World Health Organization. WHO Timeline-COVID-19. (2020). Available online at: https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19 (accessed May 7, 2020).
15. Klok FA, Kruip MJHA, van der Meer NJM, Gommers D, Kant KM, Kaptein FHI, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. (2020) 191:148–50. doi: 10.1016/j.thromres.2020.04.041
16. Friso S, Lotto V, Corrocher R, Choi SW, Vitamin B6 and cardiovascular disease. In: Stanger O, editor. Water Soluble Vitamins. Dordrecht: Springer (2012). p. 265-90. doi: 10.1007/978-94-007-2199-9_14
17. Friso S, Jacques PF, Wilson PW, Rosenberg IH, Selhub J. Low circulating vitamin B6 is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation. (2001) 103:2788–91. doi: 10.1161/01.CIR.103.23.2788
18. Huang SC, Wei JC, Wu DJ, Huang YC. Vitamin B6 supplementation improves pro-inflammatory responses in patients with rheumatoid arthritis. Eur J Clin Nutr. (2010) 64:1007–13. doi: 10.1038/ejcn.2010.107
19. Kumrungsee T, Nirmagustina DE, Arima T, Onishi K, Sato K, Kato N, et al. Novel metabolic disturbances in marginal vitamin B6-deficient rat heart. J Nutr Biochem. (2018) 65:26–34. doi: 10.1016/j.jnutbio.2018.11.004
20. Dakshinamurti S, Dakshinamurti K. Anti-inflammatory and neuroprotective actions of pyridoxine and its derivatives. Can J Physiol Pharmacol. (2015) 93:1083–90. doi: 10.1139/cjpp-2015-0098
21. Aybak M, Sernet A, Ayylidiz MO, Karakilcik AZ. Effect of oral pyridoxine hydrochloride supplementation on arterial blood pressure in patients with essential hypertensio. Arzneimittelforschung. (1995) 45:1271–3.
22. van Wyk V, Luus H G, Heyns AD. The in vivo effect in humans of pyridoxal-5’-phosphate on platelet function and blood coagulation. Thromb Res. (1992) 66:657–68.
23. Nix WA, Zirwes R, Bangert V, Kaiser RP, Schilling M, Hostalek U, et al. Effect of oral pyridoxine hydrochloride supplementation on arterial blood pressure in patients with essential hypertension. Arzneimittelforschung. (1995) 45:1271–3.
24. van Wyk V, Luus H G, Heyns AD. The in vivo effect in humans of pyridoxal-5’-phosphate on platelet function and blood coagulation. Thromb Res. (1992) 66:657–68.
25. Nix WA, Zirwes R, Bangert V, Kaiser RP, Schilling M, Hostalek U, et al. Effect of oral pyridoxine hydrochloride supplementation on arterial blood pressure in patients with essential hypertension. Arzneimittelforschung. (1995) 45:1271–3.
26. van Wyk V, Luus H G, Heyns AD. The in vivo effect in humans of pyridoxal-5’-phosphate on platelet function and blood coagulation. Thromb Res. (1992) 66:657–68.
27. Nix WA, Zirwes R, Bangert V, Kaiser RP, Schilling M, Hostalek U, et al. Effect of oral pyridoxine hydrochloride supplementation on arterial blood pressure in patients with essential hypertension. Arzneimittelforschung. (1995) 45:1271–3.
proinflammatory cytokines in experimental diabetic nephropathy. *Exp Biol Med (Maywood).* (2013) 238:881–8. doi: 10.1177/1535370213494644

28. Shan MR, Zhou SN, Fu CN, Song JW, Wang XQ, Bai WW, et al. Vitamin B6 inhibits macrophage activation to prevent lipopolysaccharide-induced acute pneumonia in mice. *J Cell Mol Med.* (2020) 24:3139–48. doi: 10.1111/jcmm.14983

29. Xu T, Wang C, Zhang R, Xu M, Liu R, Wei D, et al. Carnosine markedly ameliorates H9N2 swine influenza virus-induced acute lung injury. *J Gen Virol.* (2015) 96:2939–50. doi: 10.1099/ijv.0.00238

30. Zhang Q, Ju Y, Ma Y, Wang T. N-acetylcyesteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: A randomized controlled trial. *Medicine.* (2018) 97:e13087. doi: 10.1097/MD.0000000000013087

31. Kunisawa J, Kiyono H. Vitamin-mediated regulation of intestinal immunity. *Front Immunol.* (2013) 4:189. doi: 10.3389/fimmu.2013.00189

32. Kunisawa J, Kiyono H. Immunological function of sphingosine 1-phosphate in the intestine. *Nutrients.* (2012) 4:154–66. doi: 10.3390/nu4030154

33. Kunisawa J, Kurashima Y, Higuchi M, Gohda M, Ishikawa I, Ogahara I, et al. Sphingosine 1-phosphate dependence in the regulation of lymphocyte trafficking to the gut epithelium. *J Exp Med.* (2007) 204:2335–48. doi: 10.1084/jem.20062446

34. Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. *Cell.* (2014) 157:1013–22. doi: 10.1016/j.cell.2014.04.007

35. Chen IY, Moriyama M, Chang MF, Ichinohe T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. *Front Microbiol.* (2019) 10:50. doi: 10.3389/fmicb.2019.00050

36. Shi CS, Nabar NR, Huang NN, Kehrl JH. SARS-Coronavirus open reading frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes. *Cell Death Discov.* (2019) 5:101. doi: 10.1038/s41420-019-0181-7

37. Zhang P, Tsuchiya K, Kinoshita T, Kushiyama H, Suidasari S, Hatakeyama M, et al. Vitamin B6 prevents IL-1beta protein production by inhibiting NLRP3 inflammasome activation. *J Biol Chem.* (2016) 291:24517–27. doi: 10.1074/jbc.M116.743815

38. Liu D, Zeng X, Li X, Mehta JL, Wang X. Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases. *Basic Res Cardiol.* (2018) 113:5. doi: 10.1007/s00395-017-0663-9

39. Dixit VD. Nlrp3 inflammasome activation in type 2 diabetes: is it clinically relevant? *Diabetes.* (2013) 62:22–4. doi: 10.2337/db11-1115

40. Ravi Kumar S, Paudel S, Ghimire L, Bergeron S, Cai S, Zemans RL, et al. Emerging roles of inflammasomes in acute pneumonia. *Am J Respir Crit Care Med.* (2018) 197:160–71. doi: 10.1164/rccm.201707-1391PP

41. Bilski P, Li MY, Ehrenshtai M, Daub ME, Chignell CF. Vitamin B6 (pyridoxine) and its derivatives are efficient singlet oxygen quenchers and potential fungal antioxidants. *Photochem Photobiol.* (2000) 71:129–34. doi: 10.1562/0031-8655(2000)071<0129:SPBQWA.0.CO2

42. Matzxin JM, Padro D, Ristilä M, Strid A, Eriksson LA. Evidence of high •OH radical quenching efficiency by vitamin B₆. *J Phys Chem B.* (2009) 113:9629–32. doi: 10.1021/jp903023c

43. Kuwahara K, Nanri A, Pham NM, Kurotani K, Kume A, Sato M, et al. Serum vitamin B6, folic acid, and homocysteine concentrations and oxidative DNA damage in Japanese men and women. *Nutrition.* (2013) 29:1219–23. doi: 10.1016/j.nut.2013.03.014

44. Mahfouz MM, Zhou SQ, Kummerow FA. Vitamin B6 compounds are capable of reducing the superoxide radical and lipid peroxide levels induced by H₂O₂ in vascular endothelial cells in culture. *Inter J Vit Nutr Res.* (2009) 79:218–29. doi: 10.1024/0300-9831.79.4.218

45. Corsello T, Komaravelli N, Casola A. Role of hydrogen sulfide in NRF2- and sirtuin-dependent maintenance of cellular redox balance. *Antioxidants.* (2018) 7:129. doi: 10.3390/antiox7010029

46. Boldyrev AA, Aldini G, Derave W. Physiology and pathophysiology of carnosine. *Physiol Rev.* (2013) 93:1803–45. doi: 10.1152/physrev.00039.2012

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Kumrungsee, Zhang, Charikul, Yanaka and Kato. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.